The Effects of Trimetazidine on P-Wave Duration and Dispersion in Heart Failure Patients
Article first published online: 23 JAN 2009
©2009, The Authors. Journal compilation ©2009 Wiley Periodicals, Inc.
Pacing and Clinical Electrophysiology
Volume 32, Issue 2, pages 239–244, February 2009
How to Cite
GUNES, Y., TUNCER, M., GUNTEKIN, U., AKDAG, S. and GUMRUKCUOGLU, H. A. (2009), The Effects of Trimetazidine on P-Wave Duration and Dispersion in Heart Failure Patients. Pacing and Clinical Electrophysiology, 32: 239–244. doi: 10.1111/j.1540-8159.2008.02208.x
- Issue published online: 23 JAN 2009
- Article first published online: 23 JAN 2009
- Received August 14, 2008; revised September 10, 2008; accepted October 13, 2008.
- P-wave dispersion;
- heart failure
Background: P-wave duration and dispersion (PWD) have been shown to be noninvasive predictors for development of atrial fibrillation. Thus, it may be possible to attenuate atrial fibrillation risk through normalization of P-wave duration and dispersion. Trimetazidine, a metabolic modulator, has been reported to improve cardiac function in heart failure (HF) patients.
Methods: Thirty-six HF patients being treated with angiotensin inhibitors, carvedilol, spironolactone, and furosemide were prescribed trimetazidine, 20 mg three times a day. Electrocardiographic and echocardiographic examinations were obtained before and 6 months after addition of trimetazidine in HF patients and 36 healthy control group patients having normal echocardiographic examination.
Results: Maximum P-wave duration (Pmax) (106.7 ± 15.8 vs. 91.7 ± 12.7 ms) and PWD (57.2 ± 15.4 vs. 37.9 ± 16.7 ms) were significantly longer in HF patients compared to the control group. There were significant correlations of Pmax and PWD with left atrial diameter (r = 0.508, P = < 0.001 and r = 0.315, P = 0.029), left ventricular ejection fraction (LVEF) (r = 0.401, p = 0.005 and r = 0.396, P = 0.005), deceleration time (r = 0.296, P = 0.032 and r = 0.312, P = 0.035), and isovolumetric relaxation time (r = 0.265, P = 0.038 and r = 0.322, P = 0.015). There were significant improvements in LVEF (32.7 ± 6.5% to 37.2 ± 5.5%, P = 0.036), left atrial diameter (41.5 ± 6.7 to 40.3 ± 6.1 mm, P < 0.001), and Pmax (106.7 ± 15.8 to 102.2 ± 11.5 ms, P = 0.006) and PWD (57.2 ± 15.4 to 48.9 ± 10.1 ms, P < 0.001) during follow-up.
Conclusions: Trimetazidine added to optimal medical therapy in HF may improve Pmax and PWD in association with improved left ventricular function. Longer-term and larger studies are necessary to evaluate whether these findings may have clinical implications on prevention of atrial fibrillation.